Tags

Type your tag names separated by a space and hit enter

Therapeutic approaches in hereditary angioedema.
Clin Rev Allergy Immunol 2011; 41(1):114-22CR

Abstract

Hereditary angioedema (HAE) is characterized by acute attacks of edema with multiple localizations, the laryngeal angioedema being the most potentially lethal. In HAE, C1-INH impairments cause episodic increase in kallikrein activity leading to attacks of angioedema. Several therapies have recently become available to treat or to prevent HAE attacks, and others are under evaluation for this indication. Plasma-derived C1-INH, bradykinin receptor antagonists (icatibant), kallikrein inhibitors (ecallantide), or recombinant C1-INH is authorized on the market for HAE attack therapy or prophylaxis. Some of these compounds can be used exclusively to treat HAE attacks, whereas others can also be used as prophylactic therapies. Such therapies, although not available worldwide, can improve disease outcome due to their different mechanisms of action.

Authors+Show Affiliations

Gr T Popa University of Medicine and Pharmacy Iaşi, Department of Medicine II-Pulmonary Disease, Pulmonary Disease University Hospital, Iaşi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21279474

Citation

Antoniu, Sabina Antonela. "Therapeutic Approaches in Hereditary Angioedema." Clinical Reviews in Allergy & Immunology, vol. 41, no. 1, 2011, pp. 114-22.
Antoniu SA. Therapeutic approaches in hereditary angioedema. Clin Rev Allergy Immunol. 2011;41(1):114-22.
Antoniu, S. A. (2011). Therapeutic approaches in hereditary angioedema. Clinical Reviews in Allergy & Immunology, 41(1), pp. 114-22. doi:10.1007/s12016-011-8254-2.
Antoniu SA. Therapeutic Approaches in Hereditary Angioedema. Clin Rev Allergy Immunol. 2011;41(1):114-22. PubMed PMID: 21279474.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic approaches in hereditary angioedema. A1 - Antoniu,Sabina Antonela, PY - 2011/2/1/entrez PY - 2011/2/1/pubmed PY - 2011/11/16/medline SP - 114 EP - 22 JF - Clinical reviews in allergy & immunology JO - Clin Rev Allergy Immunol VL - 41 IS - 1 N2 - Hereditary angioedema (HAE) is characterized by acute attacks of edema with multiple localizations, the laryngeal angioedema being the most potentially lethal. In HAE, C1-INH impairments cause episodic increase in kallikrein activity leading to attacks of angioedema. Several therapies have recently become available to treat or to prevent HAE attacks, and others are under evaluation for this indication. Plasma-derived C1-INH, bradykinin receptor antagonists (icatibant), kallikrein inhibitors (ecallantide), or recombinant C1-INH is authorized on the market for HAE attack therapy or prophylaxis. Some of these compounds can be used exclusively to treat HAE attacks, whereas others can also be used as prophylactic therapies. Such therapies, although not available worldwide, can improve disease outcome due to their different mechanisms of action. SN - 1559-0267 UR - https://www.unboundmedicine.com/medline/citation/21279474/Therapeutic_approaches_in_hereditary_angioedema_ L2 - https://dx.doi.org/10.1007/s12016-011-8254-2 DB - PRIME DP - Unbound Medicine ER -